Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: Biodistribution and toxicity assessment of encapsulated amphotericin B

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 89, Issue , 2015, Pages 62-73

  Asthana, Shalini ^a   Jaiswal, Anil K ^a   Gupta, Pramod K ^a   Dube, Anuradha ^a   Chourasia, Manish K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Amphotericin B; Creatinine; Cytokines; Hybrid nanoparticle; Leishmaniasis; Macrophage

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; CREATININE; LIPID POLYMER HYBRID NANOPARTICLE; LIPOSOME; NANOPARTICLE; OCTADECYLAMINE; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; CATION; LIPID; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG LIVER LEVEL; DRUG POTENTIATION; DRUG STABILITY; ERYTHROCYTE; IC50; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY PARENCHYMA; MACROPHAGE; MALE; MEAN RESIDENCE TIME; MOUSE; NANOENCAPSULATION; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; SPLEEN; SUSTAINED DRUG RELEASE; TH1 CELL; TOXICITY TESTING; UREA NITROGEN BLOOD LEVEL; VISCERAL LEISHMANIASIS; ZETA POTENTIAL; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; KIDNEY; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MEDICINAL CHEMISTRY; PARASITOLOGY; PROCEDURES; TISSUE DISTRIBUTION; WISTAR RAT;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CATIONS; CHEMISTRY, PHARMACEUTICAL; IMMUNOMODULATION; KIDNEY; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPIDS; LIVER; MACROPHAGES; MALE; NANOPARTICLES; POLYMERS; RATS; RATS, WISTAR; SPLEEN; TH1 CELLS; TISSUE DISTRIBUTION;

EID: 84917710520     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.11.019     Document Type: Article

References (53)

1. K.S. Ravichandran, U. Lorenz, Engulfment of apoptotic cells: signals for a good meal, Nat. Rev. Immunol. 7 (2007) 964-974.
2. L. Guillot, R. Le Goffic, S. Bloch, N. Escriou, S. Akira, M. Chignard, M. Si-Tahar, Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus, J. Biol. Chem. 280 (2005) 5571-5580.
3. P.J. Barnes, Alveolar macrophages in chronic obstructive pulmonary disease (COPD), Cell. Mol. Biol. (2004) OL627-OL637 (Noisy-le-grand), 50 Online Pub.
4. J.H. Pahl, K.M. Kwappenberg, E.M. Varypataki, S.J. Santos, M.L. Kuijjer, S. Mohamed, J.T. Wijnen, M.J. van Tol, A.M. Cleton-Jansen, R.M. Egeler, W. Jiskoot, A.C. Lankester, M.W. Schilham, Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-gamma, J. Exp. Clin. Cancer Res. 33 (2014) 27.
5. A.C. da Fonseca, B. Badie, Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies, Clin. Dev. Immunol. 2013 (2013) 264124.
6. S. Asthana, A.K. Jaiswal, P.K. Gupta, V.K. Pawar, A. Dube, M.K. Chourasia, Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules, Antimicrob. Agents Chemother. 57 (2013) 1714-1722.
7. D.L. Clemens, B.Y. Lee, M. Xue, C.R. Thomas, H. Meng, D. Ferris, A.E. Nel, J.I. Zink, M.A. Horwitz, Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles, Antimicrob. Agents Chemother. 56 (2012) 2535-2545.
8. P. Puligujja, J. McMillan, L. Kendrick, T. Li, S. Balkundi, N. Smith, R.S. Veerubhotla, B.J. Edagwa, A.V. Kabanov, T. Bronich, H.E. Gendelman, X.M. Liu, Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections, Nanomedicine 9 (2013) 1263-1273.
9. H.W. Murray, M.J. Oca, A.M. Granger, R.D. Schreiber, Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis, J. Clin. Invest. 83 (1989) 1253-1257.
10. N. Berhe, D. Wolday, A. Hailu, Y. Abraham, A. Ali, T. Gebre-Michael, P. Desjeux, A. Sonnerborg, H. Akuffo, S. Britton, HIV viral load and response to antileishmanial chemotherapy in co-infected patients, AIDS 13 (1999) 1921-1925.
11. J. Alvar, C. Canavate, B. Gutierrez-Solar, M. Jimenez, F. Laguna, R. Lopez-Velez, R. Molina, J. Moreno, Leishmania and human immunodeficiency virus coinfection: the first 10 years, Clin. Microbiol. Rev. 10 (1997) 298-319.
12. H.W. Murray, J.D. Berman, C.R. Davies, N.G. Saravia, Advances in leishmaniasis, Lancet 366 (2005) 1561-1577.
13. J.C. Antoine, E. Prina, N. Courret, T. Lang, Leishmania spp.: on the interactions they establish with antigen-presenting cells of their mammalian hosts, Adv. Parasitol. 58 (2004) 1-68.
14. B. Dupont, Overview of the lipid formulations of amphotericin B, J. Antimicrob. Chemother. 49 (Suppl. 1) (2002) 31-36.
15. J.W. Hiemenz, T.J. Walsh, Lipid formulations of amphotericin B: recent progress and future directions, Clin. Infect. Dis. 22 (Suppl 2) (1996) S133-S144.
16. R.A. Jain, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials 21 (2000) 2475-2490.
17. F. Afrin, T. Dey, K. Anam, N. Ali, Leishmanicidal activity of stearylamine-bearing liposomes in vitro, J. Parasitol. 87 (2001) 188-193.
18. R. Garg, S.K. Gupta, P. Tripathi, S. Naik, S. Sundar, A. Dube, Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani, Clin. Exp. Immunol. 140 (2005) 149-156.
19. A. Dube, N. Singh, S. Sundar, Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models, Parasitol. Res. 96 (2005) 216-223.
20. P.K. Gupta, A.K. Jaiswal, V. Kumar, A. Verma, P. Dwivedi, A. Dube, P.R. Mishra, Covalent Functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation, Mol. Pharm. (2014).
21. P.W. Heng, L.W. Chan, M.G. Easterbrook, X. Li, Investigation of the influence of mean HPMC particle size and number of polymer particles on the release of aspirin from swellable hydrophilic matrix tablets, J. Control. Release 76 (2001) 39-49.
22. P.K. Gupta, S. Asthana, A.K. Jaiswal, V. Kumar, A. Verma, P. Shukla, P. Dwivedi, A. Dube, P.R. Mishra, Exploitation of lectinized lipo-polymerosome bearing amphotericin B to target macrophages for effective management of visceral leishmaniasis, Bioconjug. Chem. (2014).
23. P.C. Melby, V.V. Tryon, B. Chandrasekar, G.L. Freeman, Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis, Infect. Immun. 66 (1998) 2135-2142.
24. A.A. Seymour, J.H. Sheldon, P.L. Smith, M. Asaad, W.L. Rogers, Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs, J. Pharmacol. Exp. Ther. 269 (1994) 263-270.
25. P.J. Smith, J.A. Olson, D. Constable, J. Schwartz, R.T. Proffitt, J.P. Adler-Moore, Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B, J. Antimicrob. Chemother. 59 (2007) 941-951.
26. G.W. Boswell, I. Bekersky, D. Buell, R. Hiles, T.J. Walsh, Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats, Antimicrob. Agents Chemother. 42 (1998) 263-268.
27. S.A. Costa Lima, M. Resende, R. Silvestre, J. Tavares, A. Ouaissi, P.K. Lin, A. Cordeiro-da-Silva, Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies, Nanomedicine (Lond.) 7 (2012) 1839-1849.
28. S. Asthana, P.K. Gupta, M. Chaurasia, A. Dube, M.K. Chourasia, Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos, Expert Opin. Drug Deliv. 10 (2013) 1633-1651.
29. E. Kupetz, L. Preu, C. Kunick, H. Bunjes, Parenteral formulation of an antileishmanial drug candidate-tackling poor solubility, chemical instability, and polymorphism, Eur. J. Pharm. Biopharm. 85 (2013) 511-520.
30. K. Hadinoto, A. Sundaresan, W.S. Cheow, Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review, Eur. J. Pharm. Biopharm. 85 (2013) 427-443.
31. I. De Miguel, L. Imbertie, V. Rieumajou, M. Major, R. Kravtzoff, D. Betbeder, Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers, Pharm. Res. 17 (2000) 817-824.
32. E.M. Collnot, C. Baldes, M.F. Wempe, J. Hyatt, L. Navarro, K.J. Edgar, U.F. Schaefer, C.M. Lehr, Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers, J. Control. Release 111 (2006) 35-40.
33. E.M. Collnot, C. Baldes, M.F. Wempe, R. Kappl, J. Huttermann, J.A. Hyatt, K.J. Edgar, U.F. Schaefer, C.M. Lehr, Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity, Mol. Pharm. 4 (2007) 465-474.
34. C. Foged, B. Brodin, S. Frokjaer, A. Sundblad, Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model, Int. J. Pharm. 298 (2005) 315-322.
35. C.M. Wiethoff, J.G. Smith, G.S. Koe, C.R. Middaugh, The potential role of proteoglycans in cationic lipid-mediated gene delivery. Studies of the interaction of cationic lipid-DNA complexes with model glycosaminoglycans, J. Biol. Chem. 276 (2001) 32806-32813.
36. M. Nahar, D. Mishra, V. Dubey, N.K. Jain, Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles, Nanomedicine 4 (2008) 252-261.
37. W. Tiyaboonchai, N. Limpeanchob, Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles, Int. J. Pharm. 329 (2007) 142-149.
38. L. Das, N. Datta, S. Bandyopadhyay, P.K. Das, Successful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favorable T cell response, J. Immunol. 166 (2001) 4020-4028.
39. J. Alexander, K. Bryson, T helper (h)1/Th2 and Leishmania: paradox rather than paradigm, Immunol. Lett. 99 (2005) 17-23.
40. K.A. Rogers, G.K. DeKrey, M.L. Mbow, R.D. Gillespie, C.I. Brodskyn, R.G. Titus, Type 1 and type 2 responses to Leishmania major, FEMS Microbiol. Lett. 209 (2002) 1-7.
41. F.Y. Liew, X.Q. Wei, L. Proudfoot, Cytokines and nitric oxide as effector molecules against parasitic infections, Philos. Trans. Roy. Soc. Lond. B: Biol. Sci. 352 (1997) 1311-1315.
42. J. MacMicking, Q.W. Xie, C. Nathan, Nitric oxide and macrophage function, Annu. Rev. Immunol. 15 (1997) 323-350.
43. C.A. Nacy, Macrophage activation to kill Leishmania tropica: characterization of a T cell-derived factor that suppresses lymphokine-induced intracellular destruction of amastigotes, J. Immunol. 133 (1984) 448-453.
44. R. Basu, S. Bhaumik, J.M. Basu, K. Naskar, T. De, S. Roy, Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis, J. Immunol. 174 (2005) 7160-7171.
45. G. Trinchieri, Interleukin-12 and the regulation of innate resistance and adaptive immunity, Nat. Rev. Immunol. 3 (2003) 133-146.
46. E.E. Murphy, G. Terres, S.E. Macatonia, C.S. Hsieh, J. Mattson, L. Lanier, M. Wysocka, G. Trinchieri, K. Murphy, A. O'Garra, B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation, J. Exp. Med. 180 (1994) 223-231.
47. T. Dey, K. Anam, F. Afrin, N. Ali, Antileishmanial activities of stearylamine-bearing liposomes, Antimicrob. Agents Chemother. 44 (2000) 1739-1742.
48. P.F. Pimenta, W. de Souza, Leishmania mexicana amazonensis: surface charge of amastigote and promastigote forms, Exp. Parasitol. 56 (1983) 194-206.
49. D.M. Dwyer, Leishmania donovani: surface membrane carbohydrates of promastigotes, Exp. Parasitol. 41 (1977) 341-358.
50. D.L. King, Y.D. Chang, S.J. Turco, Cell surface lipophosphoglycan of Leishmania donovani, Mol. Biochem. Parasitol. 24 (1987) 47-53.
51. A. Banerjee, J. Roychoudhury, N. Ali, Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine, J. Antimicrob. Chemother. 61 (2008) 103-110.
52. K.M. Wasan, R.E. Morton, M.G. Rosenblum, G. Lopez-Berestein, Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein, J. Pharm. Sci. 83 (1994) 1006-1010.
53. A. Gupta, S. Asthana, R. Konwar, M.K. Chourasia, An insight into potential of nanoparticles-assisted chemotherapy of cancer using gemcitabine and its fatty acid prodrug: a comparative study, J. Biomed. Nanotechnol. 9 (2013) 915-925.